Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Penile Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
0 drugs · 0 active trials
no drug at this stage
0 drugs · 0 active trials
no drug at this stage
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cisplatin | Phase 3 | Phase 3 | 2 | 0 | 1 | 5 | 0 | — | — | 1999-08 |
| Ifosfamide | Phase 3 | Phase 3 | 1 | 0 | 1 | 3 | 0 | — | — | 1999-08 |
| Paclitaxel | Phase 3 | Phase 3 | 1 | 0 | 1 | 3 | 0 | — | — | 1999-08 |
| Nivolumab | Phase 2 | Phase 2 | 5 | 1 | 0 | 5 | 0 | — | — | Jul 22, 2015 |
| Ipilimumab | Phase 2 | Phase 2 | 4 | 1 | 0 | 4 | 0 | — | — | Jul 22, 2015 |
| Avelumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 4 | 0 | — | — | Sep 1, 2017 |
| Cabozantinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 4 | 0 | — | — | Jul 22, 2015 |
| Aldesleukin | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | Apr 13, 2012 |
| Pembrolizumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | Aug 15, 2016 |
| Atezolizumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Mar 3, 2017 |
| Enfortumab Vedotin | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Dec 21, 2023 |
| Cyclophosphamide | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 13, 2012 |
| Fludarabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 13, 2012 |
| Niraparib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Aug 29, 2017 |
| Amivantamab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2026-11 |
| Bevacizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Mar 3, 2017 |
| Carboplatin/Paclitaxel Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 13, 2024 |
| Cemiplimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2025-12 |
| Dostarlimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 28, 2022 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 1, 2024 |
| Afatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-10 |
| Cetuximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-02 |
| Docetaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-10 |
| Durvalumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 14, 2018 |
| Fluorouracil | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 29, 2017 |
| Irinotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-06 |
| Nab-paclitaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 12, 2020 |
| Nimotuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 12, 2020 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-01 |
| Retifanlimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 28, 2020 |
| Rigosertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-03 |
| Elimusertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 25, 2021 |
| Gemcitabine | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 25, 2021 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.